Thromboseprophylaxe und perioperative Therapie mit Antikoagulantien

Translated title of the contribution: Thromboprophylaxis and perioperative anticoagulant therapy

Martin Hoffmann*, Stefan Limmer, Erik Schlöricke, Hans Peter Bruch, Elke Muhl, Peter Kujath

*Corresponding author for this work


Perioperative thromboprophylactic therapy is performed with low-molecular-weight heparin (LMWH) in most cases in Germany. When administering LMWH to patients, attention needs to be paid to individual renal function. In patients with impaired renal function, the dose of the anticoagulant must be adapted where necessary. LMWH are also the standard of care in the so-called bridging therapy. The term bridging is used as a description for the cessation of the use of an oral vitamin K antagonist and the use of an alternative anticoagulant. Recent data showed that the extent of the anticoagulation during the bridging period might have been too distinct. In patients with low to medium risk for developing arterial or venous thrombembolism, the high-risk thromboprophylaxis dosage of enoxaparin or nadroparin seems to be sufficient for adequate prevention of thrombembolism. A special focus must be on previous acute coronary syndromes or coronary stent implantation when stopping single or dual anti-platelet therapy. Non-critical stopping without adherence to current position papers and guidelines may have lethal consequences for the patient.

Translated title of the contributionThromboprophylaxis and perioperative anticoagulant therapy
Original languageGerman
JournalViszeralmedizin: Gastrointestinal Medicine and Surgery
Issue number1
Pages (from-to)75-81
Number of pages7
Publication statusPublished - 01.02.2011


Dive into the research topics of 'Thromboprophylaxis and perioperative anticoagulant therapy'. Together they form a unique fingerprint.

Cite this